sorafenib / Generic mfg. - LARVOL DELTA

Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC (clinicaltrials.gov) - P=N/A | N=48 | Completed | Sponsor: AstraZeneca | Recruiting ➔ Completed | N=150 ➔ 48

Enrollment change • Real-world evidence • Trial completion • Genito-urinary Cancer • Oncology • Papillary Renal Cell Carcinoma • Renal Cell Carcinoma • Solid Tumor

Inhibition of sodium-glucose cotransporter 2 prevents sorafenib-induced depression-like behaviors by preserving hippocampal-dependent long-term potentiation. (PubMed, Pharmacol Biochem Behav) - "Co-treatment with empagliflozin effectively prevented these neurological and cellular changes. Inhibition of sodium-glucose cotransporter-2 prevents sorafenib-induced depression-like behaviors and suppresses the decline in synaptic transmission and LTP in the hippocampus, thereby contributing to the antidepressant effects of empagliflozin."

Journal • Cardiovascular • CNS Disorders • Depression • Mood Disorders • Psychiatry

Nirogacestat Compared With a Historical Sorafenib Cohort Selected for Disease Control in Desmoid Tumors: A Single-Center Real-World Experience (ESMO 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Desmoid Tumors • Oncology • Sarcoma

Safety Landscape of Bevacizumab-Based Therapies versus Sorafenib for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (ESMO 2026) - No abstract available

Metastases • Retrospective data • Review • Hepatocellular Cancer • Oncology • Solid Tumor

Impact of time toxicity from atezolizumab–bevacizumab versus sorafenib: a post hoc exploratory analysis of IMbrave150 trial in unresectable HCC (ESMO 2026) - No abstract available

Retrospective data • Hepatocellular Cancer • Oncology

Characterization of Patients who are Progression-Free at 6 Months with atezolizumab plus bevacizumab or sorafenib: Post-Hoc Analysis of the IMbrave150 trial (ESMO 2026) - No abstract available

Clinical • Retrospective data • Oncology

When should we stop? Safety, efficacy and treatment duration of sorafenib in real-world patients with desmoid tumours (ESMO 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Desmoid Tumors • Oncology • Sarcoma

Sorafenib in Desmoid-Type Fibromatosis: A Prospective Longitudinal Assessment of Cardiovascular, Endocrine, and Cognitive functions (ESMO 2026) - No abstract available

Clinical • Oncology • Sarcoma • Solid Tumor

Locoregional Treatment Outcomes of Hepatocellular Carcinoma Defined by Large Tumor Size or Macrovascular Invasion with Yttrium-90 Radioembolization and Stereotactic Body Radiation Therapy (ASTRO 2026) - "RTOG 1112 demonstrated a survival benefit of SBRT over sorafenib alone with a median tumor size of 7.8 cm and MVI rate of 74%... For large size HCC, durable locoregional control may be more difficult to achieve with Y-90 due to the inhomogeneous delivery of ablative doses compared to more homogenous tumor coverage with SBRT. For interval waiting times <=6 mo. to surgery, Y-90 may be logistically advantageous."

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

Stereotactic Body Radiation Therapy Combined with Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Comprehensive Meta-Analysis (ASTRO 2026) - "Given randomized evidence for survival benefit with SBRT with sorafenib, we performed a systematic review and meta-analysis to assess whether the combination of SBRT and ICI would improve survival and response outcomes with acceptable toxicity... SBRT plus ICI demonstrated meaningful clinical benefit, with median OS >20 months and acceptable toxicity (11.1%). Despite limitations including single-arm design and lack of randomized comparisons, findings support the biological rationale for SBRT-mediated immune potentiation pending results of activated phase three studies."

Checkpoint inhibition • Retrospective data • Hepatocellular Cancer • Oncology • Solid Tumor

Impact of early antibiotic exposure on efficacy of camrelizumab plus rivoceranib versus sorafenib in patients with unresectable hepatocellular carcinoma (uHCC): a sub-analysis of CARES-310. (ESMO 2026) - No abstract available

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

Lipophilic and Hydrophilic Statins Differentially Sensitize HepG2 Hepatocellular Carcinoma Cells to Sorafenib-Induced Cytotoxicity: An In-Vitro Study (ACG 2026) - "Sorafenib demonstrated an IC50 of 5.62 µg/mL. Atorvastatin and rosuvastatin showed antiproliferative activity against HepG2 cells, with IC50 values of 43.58 µg/mL and 50.92 µg/mL, respectively. In the presence of fixed-dose sorafenib, the IC50 of atorvastatin decreased to 30.46 µg/mL, while the IC50 of rosuvastatin decreased to 42.93 µg/mL."

Preclinical • Hepatocellular Cancer • Metabolic Disorders • Oncology • Solid Tumor

Sex Differences in GI Treatment Response Hidden by a Reporting Vacuum: A Disease Burden-Adjusted Analysis of Sex Representation, Outcome Reporting, and Sex-Specific Effects in 2,328 GI Trials (ACG 2026) - P3 | "Among 9 trials with sex-stratified estimates, F/M effect ratios diverged: sorafenib + SBRT for HCC (F/M = 0.63 OS); adjuvant chemotherapy for pancreatic cancer (0.77); mirikizumab in pediatric IBD growth velocity (0.36); and HBV vaccine response (OR = 1.90). A total of 2,328 studies, including 574,244 patients, were analyzed. Females comprised 47.2% (95% CI: 47.1%-47.4%; PPR 0.93). The proportion of females participating varied significantly by disease category; females were underrepresented in Barrett's esophagus (PPR 0.79) and overrepresented in MASLD/MASH (PPR 1.39), pancreatitis (PPR 1.34), and eosinophilic esophagitis (PPR 1.26)."

Barrett Esophagus • Eosinophilic Esophagitis • Gastrointestinal Disorder • Hepatology • Immunology • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Pancreatic Cancer • Pancreatitis • Solid Tumor

Effectiveness and Resource Utilization Following Endoscopic Sleeve Gastroplasty: Systematic Review and Meta-Analysis (ACG 2026) - "A comprehensive literature search was performed using major medical databases, including PubMed, Google Scholar and ScienceDirect to identify relevant studies comparing combination therapy with sorafenib in patients with advanced hepatocellular carcinoma... The healthcare utilisation rates were assessed by multiple outcomes, including duration of procedure and stay, readmission rates and reintervention rates. The duration of the stay was significantly shorter in the endoscopic group (-1.32(-2.26;-0.38) , p< 0.001) , the risk of reintervention rates(2.19 (1.10:4.37) , p = 0.004) and readmission rates (1.44(1.29:1.61) , p = 0.2416) was higher in the conventional laparoscopic group. Endoscopic sleeve gastroplasty is associated with lower healthcare resource utilization, reflected by significantly shorter hospital stays and reduced rates of readmission and re-intervention compared with conventional laparoscopic bariatric procedures."

HEOR • Retrospective data • Review • Genetic Disorders • Hepatocellular Cancer • Obesity • Solid Tumor

Desmoid-Type Fibromatosis for the Gastroenterologist: A Practical Review of Diagnosis, Molecular Stratification, and Evidence-Based Management With Comparative Focus on Sporadic and FAP-Associated Disease (ACG 2026) - "For progressive or symptomatic disease, sorafenib improved 2-year progression-free survival compared with placebo (81% vs 36%; HR 0.13), while nirogacestat improved progression-free survival (HR 0.29) and objective response rate (41% vs 8%). The selected evidence supported active surveillance as initial management for most patients without imminent organ threat; prospective data showed spontaneous stability or regression in approximately 60%. Sporadic DTF is usually driven by CTNNB1 mutations, whereas FAP-associated disease reflects germline APC inactivation and preferentially involves the mesentery. CTNNB1 subtype may inform postoperative recurrence counseling, while APC mutation location contributes to desmoid risk stratification in FAP."

Review • Desmoid Tumors • Fibrosis • Gastrointestinal Disorder • Genetic Disorders • Sarcoma • Short Bowel Syndrome • Solid Tumor • APC • CTNNB1

Combination Therapy Versus Sorafenib for Advanced Hepatocellular Carcinoma (OS and PFS): A Systematic Review and Meta-Analysis (ACG 2026) - "The meta analysis included a total of 11 papers with 4966 patients. The pooled Hazard Ratio showed combination therapy significantly improved overall survival when compared to Sorafenib mono-therapy [HR = 0.78 (0.67; 0.90), I² = 65.2%, p = 0.0021]. Similarly in Progression-Free Survival [HR = 0.74 (0.62; 0.89), I² = 87.8%, p < 0.0001]."

Combination therapy • Metastases • Retrospective data • Review • Hepatocellular Cancer • Oncology • Solid Tumor

Sorafenib-Induced Acute Pancreatitis in Metastatic Papillary Thyroid Carcinoma: A Rare Side Effect (ACG 2026) - "Figure: CT abdomen with IV contrast showing mild peri-pancreatic fat stranding suggestive of early acute interstitial edematous Pancreatitis. Figure: Upper endoscopic ultrasound (EUS) showing a cystic lesion 22 mm x 17 mm in the pancreatic body and neck (Tissue diagnosis suggestive of micro and macro-cystic serous cyst adenoma."

Adverse events • Metastases • Cardiovascular • Diabetes • Dyslipidemia • Gastroenterology • Hypertension • Hypertriglyceridemia • Metabolic Disorders • Oncology • Pancreatitis • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Papillary Carcinoma • Type 2 Diabetes Mellitus

Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial. (PubMed, Cancer) - "At extended follow-up, cabozantinib maintained superior efficacy over a placebo in patients with previously treated RAIR-DTC with no new safety signals."

Journal • P3 data • Cardiovascular • Dermatology • Endocrine Cancer • Fatigue • Hypertension • Oncology • Solid Tumor • Thyroid Gland Carcinoma

Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study. (PubMed, J Hepatol) - P3 | "Objective response was an independent predictor of OS in individuals with unresectable HCC in REFLECT; additional studies are needed to confirm surrogacy. Participants achieving a complete or partial response by mRECIST or RECIST v1.1 had significantly longer survival vs. those with stable/progressive/non-evaluable disease."

IO biomarker • Journal • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma: A cost-effectiveness analysis. (PubMed, Cancer) - "Nivolumab plus ipilimumab is unlikely to be cost-effective as first-line therapy for unresectable HCC from US health care payer perspective. However, extended dosing interval or price reductions may render the regimen economically viable, with important implications for clinical practice, payers, and policy."

Clinical • HEOR • Journal • Hepatocellular Cancer • Oncology • Solid Tumor

The Survival Advantage of Prior Curative Hepatectomy in Patients with Hepatocellular Carcinoma Receiving First-Line Multikinase Inhibitors: A Propensity Score-Adjusted Study. (PubMed, J Hepatocell Carcinoma) - "This retrospective cohort study enrolled 203 patients with unresectable HCC receiving first-line sorafenib or lenvatinib at a single Taiwanese referral hospital (2018-2023). The better liver reserve and more favorable tumor biology that made these patients suitable candidates for surgery may persist into the systemic therapy phase. Therefore, future clinical trials might consider prespecifying prior resection as a stratification factor."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor

Treatment outcomes of multikinase and target therapy of the Portuguese cohort of Advanced Thyroid Carcinoma (ETA 2026) - "On first line 71% were treated with Lenvatinib and 10% Sorafenib while target therapy with Dabrafenib and Trametinib (DT) represented 18% of cases (50% in ATC cohort). This is the first national wide assessment of Portuguese thyroid cancer patients treated with oral systemic therapy. Molecular testing was performed in a significant percentage of patients and mainly before first line therapy. In DTC Lenvatinib and DT showed improved anti-tumour activity compared to Sorafenib while DT had better clinical tolerability."

Clinical • Metastases • Inherited Retinal Dystrophy • Oncology • Ophthalmology • Solid Tumor • Thyroid Gland Anaplastic Carcinoma • Thyroid Gland Carcinoma • BRAF • NTRK

How to manage radioiodine-refractory thyroid cancer in the era of precision medicine. (PubMed, Drugs Context) - "Three multi-kinase inhibitors have been approved for this indication: lenvatinib and sorafenib as a first-line option and cabozantinib as a second-line option...Thus, additional selective inhibitors have been approved: larotrectinib and entrectinib for NTRK + tumours, selpercatinib and pralsetinib for RET + tumours, and crizotinib, alectinib and lorlatinib for ALK + tumours. Such a personalized approach increases clinical benefit whilst minimizing adverse events. Future studies should focus on the combination of tyrosine kinase inhibitors and immune-checkpoint inhibitors; currently, there is no strong evidence that redifferentiation strategies add clinical benefit in terms of overall survival or progression-free survival."

Journal • Review • Oncology • Solid Tumor • Thyroid Gland Carcinoma • ALK • NTRK

Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) therapy for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW expanded analyses. (ASCO-GI 2025) - P3 | "These additional analyses from CheckMate 9DW demonstrate the efficacy and manageable safety of 1L NIVO + IPI in uHCC and further support its use as a potential standard-of-care treatment option in this setting. aIncludes non-CR/non-PD. CR, complete response; NR, not reached; PD, progressive disease; PR, partial response; SD, stable disease; TRAE, treatment-related adverse event."

Clinical • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. (PubMed, Lancet) - P3 | "Nivolumab plus ipilimumab showed a significant overall survival benefit versus lenvatinib or sorafenib and manageable safety in patients with previously untreated unresectable hepatocellular carcinoma. These results support nivolumab plus ipilimumab as a first-line treatment in this setting."

Journal • P3 data • Hepatocellular Cancer • Oncology • Solid Tumor • AFP